The Company’s 2017 Stock Plan (the “2017 Plan”) provides for granting stock options and restricted stock awards to employees, directors, contractors and consultants of the Company. A total of 3,182,335 shares of common stock are authorized to be issued pursuant to the 2017 Plan. As of December 31, 2023, there were 2,739,261 shares available for future grants under the 2017 Plan. The Company has not since August 2019 granted, and in the future does not intend to grant, awards under the 2017 Stock Plan.

The Company’s 2019 Omnibus Stock Incentive Plan (the “2019 Plan”) provides for granting stock options and restricted stock awards to employees, directors, contractors and consultants of the Company. During 2023 and 2022, the Company amended the 2019 Plan by adding an additional 1.7 million and 2 million of shares authorized to be issued, respectively. A total of 5,760,778 shares of common stock are authorized to be issued pursuant to the 2019 Plan. As of December 31, 2023, there were 835,951 shares available for future grants under the 2019 Plan.


	Shares	Weighted Average Grant Date Fair Value
Nonvested at December 31, 2021	717,097	$	11.02
Granted	1,097,045	8.72
Vested	(302,869)	(13.12)
Forfeited	(136,128)	(15.88)
Nonvested at December 31, 2022	1,375,145	$	14.23
Granted	829,335	4.42
Vested	(323,654)	(12.15)
Forfeited	(114,409)	(14.23)
Nonvested at December 31, 2023	1,766,417	$	10.01

At December 31, 2023, the total unrecognized compensation related to unvested restricted stock awards granted was $4.4 million which the Company expects to recognize over a period of approximately 7 months.


	Shares	Weighted Average Grant Date Fair Value
Nonvested at December 31, 2021	—	$	—
Granted	392,564	6.58
Vested	—	—
Forfeited	—	—
Nonvested at December 31, 2022	392,564	$	6.58
Granted	2,004,147	4.67
Vested	(31,321)	(7.04)
Forfeited	(174,093)	(5.10)
Nonvested at December 31, 2023	2,191,297	$	4.94

At December 31, 2023, the total unrecognized compensation related to unvested restricted stock units was granted was $6.3 million which the Company expects to recognize over a period of approximately one year.


Stock Options	Options Outstanding	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term in Years	Aggregate intrinsic value (in thousands)
Balance at December 31, 2021	43,996	$	20.46	8.5	$	510
Granted	103,711	8.22		9.67	—
Exercised	—	—		—	—
Balance at December 31, 2022	147,707	$	11.87	9.32	$	—
Granted	—	—		—	—
Exercised	—	—		—	—
Balance at December 31, 2023	147,707	$	11.87	9.32	—
Options exercisable at December 31, 2023	147,707	$	11.87	9.32	$	—

The weighted-average grant-date fair value of options granted during the year ended December 31, 2022 was $8.22 There were no options granted in the year ended December 31, 2023. At December 31, 2023, all stock option awards were vested and all related compensation expense had been recognized.

Stock based compensation related to the Company’s 2019 Plan is reported within the consolidated statement of operations as follows (amount in thousands):


	Year Ended December 31,
	2023		2022
Commission and other agent-related cost	$	3,934	$	2,920
Operations and support	614		609
Technology and development	185		79
General and administrative	7,857		5,334
Marketing	404		189
Total stock-based compensation	$	12,994	$	9,131

The Company capitalized $0 and $0.2 million of stock-based compensation expense associated with the cost of developing software for internal use during the years ended December 31, 2023 and 2022, respectively.